Don't Buy UnitedHealth Group (UNH) Stock Before Reading This

UnitedHealth (UNH) is still growing but not briskly, with Q1 revenue up 2% year over year to $112B (down from $113B in the prior quarter). The DOJ is conducting criminal and civil investigations into Medicare Advantage billing, alongside lawsuits alleging improper claim denials, and Medicare Advantage cost pressure is leading the company to shrink membership rolls by more than 1 million. Offsetting positives include a lower medical care ratio of 83.9% in Q1 (from 84.8% a year earlier) and valuation metrics like a 0.84 price-to-sales ratio versus a 1.13 five-year average.

Analysis

UNH is still a quality compounder only if the market believes earnings are policy-driven rather than investigation-driven. That belief is now weaker: in managed care, the multiple is set by visibility into medical cost trend and regulatory capital usage, and an open-ended DOJ process effectively taxes both. The reported improvement in care ratio helps at the margin, but if it is being achieved partly by pruning unprofitable lives, revenue quality falls even when margins hold.

Second-order, a deliberate exit from marginal Medicare Advantage members can stabilize UNH’s economics but it also signals that industry pricing is too tight for the current reimbursement regime. That creates a cleaner relative setup for peers with less legal overhang and better pricing power, while keeping pressure on the entire MA complex to reserve more conservatively and slow buybacks. In contrast, any provider or pharma names that depend on MA volume may see mix shifts, but the bigger effect is multiple compression on the insurers until litigation scope is clearer.

The key catalyst path is not AI spend or valuation; it is whether the investigations expand into a broader earnings-quality issue. Over the next 1-3 months, earnings guidance and any DOJ procedural step matter more than headline revenue growth, while over 6-18 months the structural variable is whether UNH can sustain an 83-84% ratio without sacrificing membership growth. Consensus appears to be underpricing the possibility of a longer de-rating, but also overestimating how much of the current weakness is immediately monetizable if no new legal facts emerge.

Key Decisions for Investors

• Avoid initiating a fresh outright long UNH here; the setup is a visibility problem, not a valuation problem, and the stock can stay range-bound until DOJ and guidance risk clears over the next 1-3 months.
• Relative-value idea: short UNH vs long XLV on a 1-3 month horizon if you want healthcare exposure without single-name legal risk; the trade works if the sector rerates on stable macro while UNH remains capped by investigation overhang.
• Use UNH 3-6 month put spreads, struck roughly 5-10% below spot, as a defined-risk hedge into earnings/DOJ updates; the payoff is best if the market starts marking a higher legal reserve or a worse MA margin trajectory.
• Watch ELV and HUM for share-transfer confirmation: if UNH continues to shrink MA membership while peers hold or gain enrollment, that supports a sector readjustment trade rather than a company-specific one.
• Falsifier for a bearish thesis: if UNH sustains sub-84% medical care ratio, reaffirms FY guidance, and there is no incremental DOJ action over 1-2 quarters, cover any short or hedge and expect the stock to trade back on cash generation.